全文获取类型
收费全文 | 33591篇 |
免费 | 3099篇 |
国内免费 | 80篇 |
专业分类
耳鼻咽喉 | 259篇 |
儿科学 | 1139篇 |
妇产科学 | 1012篇 |
基础医学 | 4656篇 |
口腔科学 | 723篇 |
临床医学 | 4690篇 |
内科学 | 5797篇 |
皮肤病学 | 490篇 |
神经病学 | 3677篇 |
特种医学 | 713篇 |
外国民族医学 | 3篇 |
外科学 | 3554篇 |
综合类 | 569篇 |
一般理论 | 55篇 |
预防医学 | 4027篇 |
眼科学 | 592篇 |
药学 | 2490篇 |
中国医学 | 38篇 |
肿瘤学 | 2286篇 |
出版年
2023年 | 235篇 |
2022年 | 248篇 |
2021年 | 604篇 |
2020年 | 439篇 |
2019年 | 681篇 |
2018年 | 767篇 |
2017年 | 614篇 |
2016年 | 626篇 |
2015年 | 709篇 |
2014年 | 1018篇 |
2013年 | 1477篇 |
2012年 | 2088篇 |
2011年 | 2172篇 |
2010年 | 1184篇 |
2009年 | 1162篇 |
2008年 | 1840篇 |
2007年 | 2054篇 |
2006年 | 2020篇 |
2005年 | 1882篇 |
2004年 | 1846篇 |
2003年 | 1693篇 |
2002年 | 1658篇 |
2001年 | 646篇 |
2000年 | 617篇 |
1999年 | 578篇 |
1998年 | 378篇 |
1997年 | 320篇 |
1996年 | 289篇 |
1995年 | 284篇 |
1994年 | 252篇 |
1993年 | 250篇 |
1992年 | 378篇 |
1991年 | 372篇 |
1990年 | 351篇 |
1989年 | 317篇 |
1988年 | 313篇 |
1987年 | 295篇 |
1986年 | 297篇 |
1985年 | 303篇 |
1984年 | 240篇 |
1983年 | 225篇 |
1982年 | 165篇 |
1981年 | 180篇 |
1980年 | 166篇 |
1979年 | 221篇 |
1978年 | 153篇 |
1977年 | 151篇 |
1976年 | 149篇 |
1974年 | 147篇 |
1973年 | 152篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
Weiyu Ye Anna Olsson-Brown Robert A. Watson Vincent T. F. Cheung Robert D. Morgan Isar Nassiri Rosalin Cooper Chelsea A. Taylor Umair Akbani Oliver Brain Rubeta N. Matin Nicholas Coupe Mark R. Middleton Mark Coles Joseph J. Sacco Miranda J. Payne Benjamin P. Fairfax 《British journal of cancer》2021,124(10):1661
Background Immune checkpoint blockers (ICBs) activate CD8+ T cells, eliciting both anti-cancer activity and immune-related adverse events (irAEs). The relationship of irAEs with baseline parameters and clinical outcome is unclear.Methods Retrospective evaluation of irAEs on survival was performed across primary (N = 144) and secondary (N = 211) independent cohorts of patients with metastatic melanoma receiving single agent (pembrolizumab/nivolumab—sICB) or combination (nivolumab and ipilimumab—cICB) checkpoint blockade. RNA from pre-treatment and post-treatment CD8+ T cells was sequenced and differential gene expression according to irAE development assessed.Results 58.3% of patients developed early irAEs and this was associated with longer progression-free (PFS) and overall survival (OS) across both cohorts (log-rank test, OS: P < 0.0001). Median survival for patients without irAEs was 16.6 months (95% CI: 10.9–33.4) versus not-reached (P = 2.8 × 10−6). Pre-treatment monocyte and neutrophil counts, but not BMI, were additional predictors of clinical outcome. Differential expression of numerous gene pathway members was observed in CD8+ T cells according to irAE development, and patients not developing irAEs demonstrating upregulated CXCR1 pre- and post-treatment.Conclusions Early irAE development post-ICB is associated with favourable survival in MM. Development of irAEs is coupled to expression of numerous gene pathways, suggesting irAE development in-part reflects baseline immune activation.Subject terms: Immunotherapy, Melanoma 相似文献
6.
ABSTRACTCommunication between health professionals and patients is an intergroup phenomenon where the health professional has the most power and status. Over the past few decades, there has been a steady increase in the availability to patients of information about healthcare and specific diseases on the Internet. In this paper, we ask whether the use of Internet health information assists patients to manage their consultations with health professionals better and whether it alters the intergroup dynamic by providing a more equal status for patients. In this study 370 participants from Australia and Canada completed a survey that included a ‘willingness to communicate with health professionals’ scale. They also commented on their use and trust of Internet health information. Thematic analysis suggests that patients’ use of Internet health information serves as a broker between patients and their health provider in health consultations. We discuss the implications of these findings for health practitioners as they address how easier Internet access influences patient interactions with health professionals. We consider future research directions these finding provide in explaining communication behaviour in this context. 相似文献
7.
8.
9.
10.
Sameer Arora Kamal Shemisa Muthiah Vaduganathan Arman Qamar Ankur Gupta Sushil K. Garg Dharam J. Kumbhani Helen Mayo Houman Khalili Ambarish Pandey Sandeep R. Das 《Journal of the American College of Cardiology》2019,73(19):2454-2464
Ticagrelor is a cornerstone of modern antithrombotic therapy alongside aspirin in patients with acute coronary syndrome and after percutaneous coronary intervention. Adverse effects such as bleeding and dyspnea have been associated with premature ticagrelor discontinuation, which may limit any potential advantage of ticagrelor over clopidogrel. The randomized trials of ticagrelor captured adverse events, offering the opportunity to more precisely quantify these effects across studies. Therefore, a meta-analysis of 4 randomized clinical trials of ticagrelor conducted between January 2007 and June 2017 was performed to quantify the incidence and causes of premature ticagrelor discontinuation. Among 66,870 patients followed for a median 18 months, premature ticagrelor discontinuation was seen in 25%; bleeding was the most common cause of discontinuation followed by dyspnea. Versus the comparators, the relative risk of dyspnea-related discontinuation during follow-up was 6.4-fold higher, the relative risk of bleeding was 3.2-fold higher, and the relative risk of discontinuation due to any adverse event was 59% higher for patients receiving ticagrelor. Understanding these potential barriers to adherence to ticagrelor is crucial for informed patient-physician decision making and can inform future efforts to improve ticagrelor adherence. This review discusses the incidence, causes, and biological mechanisms of ticagrelor-related adverse effects and offers strategies to improve adherence to ticagrelor. 相似文献